Subfoveal Choroidal Thickness as a Predictor for CSC
Published online Sept. 30, 2016
Central serous chorioretinopathy (CSC) remains poorly understood, despite its high prevalence. Ambiya et al. analyzed data from enhanced depth imaging optical coherence tomography (EDI-OCT) to evaluate the role of subfoveal choroidal thickness (CT) in the course of the disease. They found that a thinner CT (<356 μm) was more likely to indicate chronic disease requiring treatment.
In this retrospective chart review, the authors analyzed 38 treatment-naïve eyes of 33 patients (26 men, 7 women; mean age of 44.3 ± 8.8 years). Ocular history, demographics, laterality, and comorbidities were recorded; clinical examination included visual acuity, slit-lamp biomicroscopy, ophthalmoscopy, and—at the discretion of the investigator—digital fluorescein angiography with or without indocyanine green angiography. All eyes were examined with OCT, and EDI-OCT was used to measure subfoveal CT. Univariate and multivariate analyses for association of baseline features with need for treatment were performed.
On multivariate regression analysis, the authors found that only baseline subfoveal CT had a statistically significant association with the need for treatment. Specifically, the mean baseline subfoveal CT was significantly lower (307.07 μm) in eyes that required treatment with laser photocoagulation, photodynamic therapy, or both, compared with eyes that were managed with observation (420.48 μm). Based on their analyses, the authors hypothesized that 356 μm was a possible critical CT value for deciding whether to treat or observe; and they classified eyes with CT <356 μm as Group A and those with CT >356 μm as Group B.
The authors concluded that eyes in Group A were more likely to have chronic CSC that required treatment (12 of 22 eyes; 54.55%) compared with those in Group B (3 of 16 eyes; 18.75%). They also commented that EDI-OCT is an important tool for monitoring the course of CSC.
The original article can be found here.